Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/Vical

Executive Summary

Sign licensing agreement to develop vaccines for the prevention of human infectious diseases, Vical announces June 12. The vaccines will incorporate Vical's Gene Therapeutics technology, in which gene sequences from viruses are used to stimulate the production of antibodies. The three-year agreement includes undisclosed yearly research funding, milestone payments, option and license fees and royalty payments on sales of products resulting from the agreement. The agreement is the first covering San Diego-based Vical's Gene Therapeutics. The firm also has development agreements with Burroughs Wellcome and Oclassen.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel